Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis — Stella

Home/Intracranial Atherosclerosis/Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

View on ClinicalTrials.gov

Recruiting

Back to Intracranial Atherosclerosis trials

Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Singapore

National University Hospital, Singapore

Key details

Phase

Safety & dosing / Large-scale testing

Sponsor

National University of Singapore

Enrollment target

~130 participants

Started

December 2025

Primary completion

December 2030

Age range

21 Years – 80 Years

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.